SEC. 2. STUDY ON PREVALENCE AND MORTALITY OF CAN-
CER AMONG MILITARY ROTARY-WING PILOTS 
AND AVIATION SUPPORT PERSONNEL. 
(a) STUDY REQUIRED.—The Director of the Defense 
Health Agency, in coordination with the Directors of the 
National Institutes of Health and the National Cancer In-
stitute, shall conduct a study among covered individuals 
in two phases as provided by this section. 
(b) INITIAL PHASE OF STUDY.— 
(1) GOAL OF INITIAL PHASE.—Under the initial 
phase of the study under subsection (a), the Direc-
tor of the Defense Health Agency shall determine, 
for each cancer specified in paragraph (2), whether 
there is an increased prevalence of, or increased rate 
of mortality caused by, such cancer for covered indi-
viduals as compared to similarly aged individuals in 
the general population (or, in the case of the cancer 
specified in paragraph (2)(B), for female covered in-
dividuals as compared to similarly aged women in 
the general population). 
(2) CANCERS SPECIFIED.—The cancers speci-
fied in this paragraph are the following: 
(A) Brain cancer. 
(B) Breast cancer. 
(C) Colon and rectal cancer. 
(D) Kidney cancer. 
VerDate Sep 11 2014 
00:38 Jul 31, 2025
Jkt 059200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H4704.IH
H4704
ssavage on LAPJG3WLY3PROD with BILLS
(E) Lung cancer. 
(F) Melanoma. 
(G) Non-Hodgkin’s lymphoma. 
(H) Ovarian cancer. 
(I) Pancreatic cancer. 
(J) Prostate cancer. 
(K) Testicular cancer. 
(L) Urinary bladder cancer. 
(3) REPORT
ON
INITIAL
PHASE.—Not later 
than one year after the date of the enactment of this 
Act, the Director of the Defense Health Agency shall 
submit to the appropriate congressional committees 
a report on the findings of the phase of the study 
under this subsection. 
(c) SECOND PHASE OF STUDY.— 
(1) GOAL OF SECOND PHASE.—If, pursuant to 
the phase of the study under subsection (b), the Di-
rector of the Defense Health Agency determines 
there is an increased prevalence of, or increased 
mortality rate caused by, any cancer specified in 
subsection (b)(2) among covered individuals (or, 
with respect to the cancer specified in subsection 
(b)(2)(B), among female covered individuals), the 
Director shall conduct a second phase of the study 
to— 
VerDate Sep 11 2014 
00:38 Jul 31, 2025
Jkt 059200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H4704.IH
H4704
ssavage on LAPJG3WLY3PROD with BILLS
(A) identify any carcinogenic toxin or other 
hazardous material associated with the oper-
ation of military rotary-wing aircraft, such as 
fumes, fuels, or other liquids; 
(B) identify any operating environment, in-
cluding frequencies or electromagnetic fields, in 
which covered individuals may have received ex-
cess exposure to non-ionizing radiation in the 
course of such operation, including non-ionizing 
radiation associated with airborne, ground, or 
shipboard radars; and 
(C) identify potential exposures as a result 
of military service by covered individuals to car-
cinogenic toxins or other hazardous materials 
not associated with the operation of military ro-
tary-wing aircraft (such as exposure to burn 
pits, toxins in contaminated water, or toxins 
embedded in soils), including by determining— 
(i) the locations of such service; and 
(ii) any duties of covered individuals 
unrelated to such operation and associated 
with an increased prevalence of, or in-
creased mortality rate caused by, cancer. 
(2) REPORT ON SECOND PHASE.—If the Direc-
tor of the Defense Health Agency conducts the 
VerDate Sep 11 2014 
00:38 Jul 31, 2025
Jkt 059200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H4704.IH
H4704
ssavage on LAPJG3WLY3PROD with BILLS
phase of the study under this subsection, not later 
than one year after the date on which the Director 
submits the report under subsection (b)(3), the Di-
rector shall submit to the appropriate congressional 
committees a report on the findings of such phase. 
(3) DATA FORMAT.—The Director of the De-
fense Health Agency shall format any data resulting 
from the phase of the study under this subsection 
consistent with the formatting of data under the 
Surveillance, Epidemiology, and End Results pro-
gram, including by disaggregating such data by race, 
gender, and age. 
(d) SOURCES OF DATA.—In conducting the study 
under this section, the Director of the Defense Health 
Agency shall use data from— 
(1) the database of the Surveillance, Epidemi-
ology, and End Results program; 
(2) the study conducted under section 750 of 
the National Defense Authorization Act for Fiscal 
Year 2021 (Public Law 116–283; 134 Stat. 3716); 
and 
(3) any other study previously conducted by the 
Secretary of a military department that the Director 
determines relevant for purposes of this section. 
(e) DEFINITIONS.—In this section: 
VerDate Sep 11 2014 
00:38 Jul 31, 2025
Jkt 059200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6201
E:\BILLS\H4704.IH
H4704
ssavage on LAPJG3WLY3PROD with BILLS
(1) The term ‘‘appropriate congressional com-
mittees’’ means— 
(A) the Committee on Armed Services and 
the Committee on Veterans’ Affairs of the 
House of Representatives; and 
(B) the Committee on Armed Services and 
the Committee on Veterans’ Affairs of the Sen-
ate. 
(2) The term ‘‘covered Armed Force’’ means 
the Army, Navy, Marine Corps, Air Force, or Space 
Force. 
(3) The term ‘‘covered individual’’ means any 
individual who— 
(A) served in a covered Armed Force on or 
after February 28, 1961, as an aircrew member 
of a rotary-wing aircraft (including as a pilot or 
aviation support personnel), without regard to 
the status, position, rank, or grade of the indi-
vidual within such crew; and 
(B) receives health care benefits under 
chapter 55 of title 10, United States Code. 
(4) The term ‘‘Surveillance, Epidemiology, and 
End Results program’’ means the program of the 
National Cancer Institute referred to in section 
VerDate Sep 11 2014 
00:38 Jul 31, 2025
Jkt 059200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6201
E:\BILLS\H4704.IH
H4704
ssavage on LAPJG3WLY3PROD with BILLS
399B(d)(1) of the Public Health Service Act (40 
U.S.C. 280e(d)(1)), or any successor program. 
Æ 
VerDate Sep 11 2014 
00:38 Jul 31, 2025
Jkt 059200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6301
E:\BILLS\H4704.IH
H4704
ssavage on LAPJG3WLY3PROD with BILLS